Filtered By:
Condition: Atrial Fibrillation
Management: Healthcare Costs

This page shows you your search results in order of date.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
ConclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and  ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research

Impact of preoperative atrial fibrillation on in-hospital outcomes of coronary artery bypass grafting
The objective of our study was to assess if preoperative AF in patients undergoing coronary artery bypass grafting is a predictor of operative mortality, postoperative stroke and need for postoperative dialysis by interrogating a large registry database.
Source: Seminars in Thoracic and Cardiovascular Surgery - July 13, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Daniel Paul Fudulu, Arnaldo Dimagli, Shubhra Sinha, James Ackah, Pradeep Narayan, Jeremy Chan, Marco Gemelli, Tim Dong, Umberto Benedetto, Gianni Davide Angelini Tags: ADULT – Original Submission Source Type: research

EE411 Healthcare Costs of Direct Oral Anticoagulants Among Medicare Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
To evaluate cost differences between stroke/systemic embolism (S/SE) and major bleeding (MB) among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity prescribed direct oral anticoagulants (DOACs) or warfarin.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, R Thomas, G Leung, B Emir, H Yuce, M DiFusco Source Type: research

Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol
Introduction The burden of atrial fibrillation (AF) in Thailand is high and associated with increased morbidity, mortality and healthcare costs. Vitamin K antagonists (eg, warfarin), commonly used for stroke prevention in patients with AF in Thailand, are effective but are often suboptimally controlled. We aim to evaluate the impact of an SAMe-TT2R2 score-guided strategy and educational intervention compared to usual care on anticoagulation control expressed by the time in therapeutic range (TTR) at 12 months, in anticoagulant-naïve Thai patients with AF. Methods and analysis Multicentre, open-label, parallel-grou...
Source: BMJ Open - October 11, 2021 Category: General Medicine Authors: Phrommintikul, A., Nathisuwan, S., Gunaparn, S., Krittayaphong, R., Wongcharoen, W., Sehmi, S., Mehta, S., Winkles, N., Brocklehurst, P., Mathers, J., Jowett, S., Jolly, K., Lane, D., Thomas, G. N., Lip, G. Y. H., TREATS-AF Study Group, Prasertwitayakij, Tags: Open access, Medical management Source Type: research

The incidence of stroke in patients with early echocardiography after acute myocardial infarction
AbstractLeft ventricular (LV) thrombus formation after ST-elevation myocardial infarction (STEMI) increases the risk of stroke. In our center, most echocardiograms are performed within 2  days post-STEMI. However, LV thrombi often become visible later. We assessed the 1-year incidence of stroke in patients without LV thrombus on echocardiography performed early (1–2 days) vs. later (day ≥ 3) post-STEMI. This retrospective observational study included 416 patients with acut e STEMI. Patients with atrial fibrillation were excluded. All patients underwent echocardiography during admission. Patients with stroke withi...
Source: The International Journal of Cardiovascular Imaging - July 12, 2021 Category: Radiology Source Type: research

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization
CONCLUSION: Patients with PAD who experience major atherothrombotic vascular events post-revascularization have considerably higher healthcare resource use and costs compared with similar metrics pre-revascularization. Therefore, reducing the rate of such events could reduce overall healthcare costs for this population.PMID:33634723 | DOI:10.1080/13696998.2021.1891089
Source: Journal of Medical Economics - February 26, 2021 Category: Health Management Authors: Urvi Desai Akshay Kharat Connie N Hess Dejan Milentijevic Fran çois Laliberté Peter Zuckerman John Benson Patrick Lefebvre William R Hiatt Marc P Bonaca Source Type: research

Healthcare costs before and after stroke in non-valvular atrial fibrillation patients who initiated treatment with rivaroxaban or warfarin.
CONCLUSIONS: Total all-cause costs of care increased in the post-stroke period, and particularly in the patients treated with warfarin relative to those treated with rivaroxaban. The lower rate of stroke in the rivaroxaban cohort suggests that greater pre- to post-stroke cost increases result from more strokes occurring in the warfarin cohort. PMID: 33499689 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 29, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting
ConclusionIn this SNF setting, HCRU and costs were lower among patients with NVAF who were experienced users of rivaroxaban compared with those who were experienced users of warfarin. These findings may help inform clinical decision making to reduce the economic burden of NVAF among older adults in SNFs.
Source: Drugs and Aging - March 8, 2020 Category: Geriatrics Source Type: research